Adult T-cell leukemia (ATL) is an aggressive malignancy caused by human T-cell lymphotropic virus-1. There is no accepted curative therapy for ATL. We have reported that certain ATL patients have increased Notch-1 signaling along with constitutive activation of the nuclear factor-κB pathway. Physical and functional interaction between these two pathways provides the rationale to combine the γ-secretase inhibitor compound E with the proteasome inhibitor bortezomib. Moreover, romidepsin, a histone deacetylase inhibitor, has demonstrated major antitumor action in leukemia/lymphoma. In this study, we investigated the therapeutic efficacy of the single agents and the combination of these agents in a murine model of human ATL, the MT-1 model. Single and double agents inhibited tumor growth as monitored by tumor size (P o 0.05), and prolonged survival of leukemia-bearing mice (P o 0.05) compared with the control group. The combination of three agents significantly enhanced the antitumor efficacy as assessed by tumor size, tumor markers in the serum (human soluble interleukin-2 receptor-α and β 2 -microglobulin) and survival of the MT-1 tumor-bearing mice, compared with all other treatment groups (P o 0.05). Improved therapeutic efficacy obtained by combining compound E, bortezomib and romidepsin supports a clinical trial of this combination in the treatment of ATL.
INTRODUCTION
Human T-cell lymphotropic virus-1 (HTLV-1)-associated adult T-cell leukemia (ATL) is an aggressive leukemia/lymphoma of CD3 dim CD4 + CD25 + T cells. 1,2 HTLV-1-mediated T-cell transformation is a multistep oncogenic process in which virus-induced chronic T-cell proliferation results in the accumulation of genetic defects and dysregulated growth of infected cells. Of the 15-20 million HTLV-1-infected carriers worldwide,~500 000 will ultimately develop ATL, a leukemia that is highly refractory to conventional therapy. Despite intensive efforts to improve the overall survival, ATL remains one of the hematologic malignancies with the poorest prognosis. At present, there is no accepted curative therapy for ATL, and patients with acute ATL have a median survival rate of 13 months. 3 The poor prognosis of ATL is mainly associated with its resistance to chemotherapy. Therefore, exploring novel innovative therapeutic strategies for ATL is critical.
ATL is typically preceded by decades of clinical latency during which HTLV-1-infected cells accumulate selectable traits leading to a malignant transformation. Although the precise mechanism is not completely understood, host pathways commandeered by the virus have provided therapeutic targets of benefit to patients. Constitutively activated Notch-1 and nuclear factor-κB (NF-κB) pathways have emerged as valuable targets in ATL.
Notch-1 is a single-transmembrane receptor composed of extracellular, transmembrane and intracellular subunits linked via heterodimerization domains. 4, 5 Mammals have four Notch receptors (Notch-1-Notch-4) and five DSL ligands (Jagged-1, Jagged-2, delta-like-1 (DLL-1), DLL-3 and DLL-4). 6 Ligand binding induces proteolytic cleavage of the receptor by several proteases (including γ-secretases), resulting in the release of an intracellular fragment of Notch-1 (ICN-1), which translocates to the nucleus and activates the transcription of downstream genes. Notch signaling is important in many developmental contexts and this is well exemplified by its role in cells of hematopoietic lineage. 6 Fifty percent of patients with acute T-lymphoblastic leukemia/ lymphoma (T-ALL) have been demonstrated to carry activating mutations of Notch-1, 7 and in our study we demonstrated activating PEST domain Notch-1 mutations in 40% of ATL patients. 8 The identification of Notch-1 as a potential oncogene in ATL opened the way for efforts to elucidate the signaling pathways involved in Notch-1-induced transformation.
NF-κB pathway is an important regulator of cell survival, cell cycle progression, cell adhesion and migration. 9, 10 These processes, when deregulated, are the hallmarks of tumor induction. The NF-κB pathway has been implicated in a variety of human cancers including the development of ATL. It has been demonstrated that T-cell transformation by HTLV-1 involves the deregulation and constitutive signaling of NF-κB. [11] [12] [13] These studies provide the scientific basis for targeting of NF-κB pathway in ATL.
Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histones, resulting in the compaction of chromatin and the prevention of gene transcription. HDAC inhibitors reverse this process and induce apoptosis. 14, 15 Romidepsin is a cyclin tetrapeptide HDAC inhibitor. In 2009, the Food and Drug Administration granted approval for the treatment of cutaneous T-cell lymphoma patients with romidepsin. Moreover, romidepsin has shown cytotoxic effects on malignant lymphoid cell lines, including HTLV-1-infected T-cell lines. 16, 17 In the present study, using a murine ATL model (MT-1), we investigated the therapeutic efficacy of three reagents alone or in combination. Compound E was used as a γ-secretase inhibitor (GSI); bortezomib as the proteasome inhibitor to block NF-κB activity; and romidepsin as an HDAC inhibitor. Each of three reagents alone or in double combination inhibited tumor growth as monitored by tumor size, the level of tumor markers in the serum and significantly prolonged the survival of tumor-bearing animals (P o0.05). The combination of three reagents provided much greater therapeutic efficacy in the MT-1 ATL model and the median survival of tumor bearing animals was significantly prolonged when compared with all other treatment groups. Some of the triple combination-treated animals had no detectable tumors at the end of study. Our data provide the scientific basis for the combination treatment of ATL patients with a GSI, bortezomib and romidepsin.
MATERIALS AND METHODS Drug
Compound E was obtained from Enzo Life Sciences Inc. (Farmingdale, NY, USA). Bortezomib, RO4929097 (another GSI) and romidepsin were purchased from SelleckChemical.com (Houston, TX, USA).
Cells and inhibitory assay
Informed consent was obtained in accordance with the Declaration of Helsinki and was approved by the Investigational Review Board of National Cancer Institute (NCI). Peripheral blood mononuclear cells (PBMCs) were isolated from ATL patients by Ficoll-Hypaque. ATL subtypes were classified according to the diagnostic criteria proposed by Shimoyama et al. 18 ATL cell lines MT-1, ED40515 (+) (ED+), ED40515 (− ) (ED − ), 43Tb − , LM-Y1, ED41214 − and ST-1, as well as Hut-102 (HTLV-1-infected cell line from a patient with ATL), Jurkat, HPB-ALL (T-ALL lines) and Kit225 (chronic T-cell lymphocytic leukemia) were used. The BJ fibroblast cell line and HCT-15 were used as controls. The inhibitory effects of inhibitors on cell growth were assayed by measuring [ 3 H]thymidine incorporation. PBMCs from ATL patients were cultured ex vivo in the presence of inhibitors. On day 6 of the culture, 3 H-TdR was added for the last 6 h. Cell proliferation was measured by thymidine incorporation. Detailed information is provided in Supplementary Materials and methods.
Reverse transcription-PCR, sequencing and transfection
Quantitative PCR was performed with total RNA from MT-1 cells. The amplified PCR product was purified and was directly sequenced. Wild-type human ICN-1 was transfected into 293T cells. Detailed information is provided in Supplementary Materials and methods.
Measurement of apoptotic cell death and caspase activity
For detection of apoptosis, Annexin-V-binding capacities of the treated cells were examined by flow cytometry using an Annexin-V-FITC/PI Apoptosis Detection Kit (eBioscience, San Diego, CA, USA), according to the manufacturer's instructions. For PBMCs from ATL patients, the percentages of specific apoptosis were calculated as follows: %specific apoptosis = (Annexin-V + − spontaneous Annexin-V + )/(100 − spontaneous Annexin-V + ) ×100. The caspase-3 and -9 activities were measured using caspase-3 and -9 colorimetric assays from R&D Systems (Minneapolis, MN, USA).
Western blot analysis
Samples from whole-cell lysates were prepared and proteins (30 μg) were subjected to western blot analysis. 8 The blots were probed with antibodies to cleaved human Notch-1 (Val 1744) and β-actin (Cell Signaling, Danvers, MA, USA).
SiRNA transfections and cell viability analysis
MT-1 cells were transfected with Notch-1-small interfering RNA (siRNA) and control-siRNA, respectively, using siRNA Transfection Kits from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) following the manufacturer's instructions. We determined changes in cell viability by Annexin-V-FITC/ propidium iodide (PI) staining and analyzed by flow cytometry.
Cell cycle analysis
The cells were synchronized in G 0 by serum starvation for 24 h in phenol red-free RPMI with 0.1% serum. Subsequently, cells were released into medium containing 10% fetal bovine serum. Cells were fixed in 70% alcohol for 30 min at 4°C. Then, cells were resuspended in phosphatebuffered saline with PI and RNase-A for 30 min at 37°C. Samples were analyzed for DNA content using a FACSCalibur (BD Biosciences, San Jose, CA, USA).
NF-κB transcription factor DNA-binding assays
To measure the activity of NF-κB pathway, levels of nuclear DNA-binding NF-κB subunits were assessed using TransAM NF-κB Family Kit (Active Motif, Carlsbad, CA, USA). Fractionated protein lysates were prepared and the nuclear fractions were incubated on a 96-well plate containing immobilized NF-κB consensus oligonucleotides. Bound NF-κB complexes were detected using specific antibodies directed against the different subunits, and quantified using a horseradish peroxidase-based colorimetric readout.
Mouse model of ATL
MT-1 cells (1 × 10 7 ) were subcutaneously injected into NOG (NOD/Shi-scid/ IL-2Rγ-null) mice to establish a tumor model. MT-1 cells have a characteristic ATL phenotype elucidated by flow cytometric analysis:
. Therapeutic experiments were performed on selected mice with palpable tumors. All animal experiments were performed in accordance with NIH Animal Care and Use Committee guidelines.
Therapeutic study
Compound E was dissolved in polyethylene glycol-300 (VWR Scientific Products, Radnor, PA, USA) at 10 μmol/kg, and continuously administered via a subcutaneous mini-osmotic pump (ALZET, Cupertino, CA, USA) for 28 days. Bortezomib was provided at 0.5 mg/kg per injection by intraperitoneal injection two times weekly for 4 weeks. Romidepsin was administrated at 0.5 mg/kg by intraperitoneal injection every other day for 4 weeks. One group of mice that received 200 μl phosphate-buffered saline weekly for 4 weeks served as a control.
Monitoring tumor growth
Tumors were measured weekly, tumor size was calculated as mm 3 = 0.5 × length (mm) × width 2 (mm). The measurements of the serum concentrations of human sIL-2Rα (sIL-2Rα) or β 2 -microglobulin (β 2 M) were performed using ELISA (R&D Systems, Minneapolis, MN, USA) following the manufacturer's recommendations.
Surface and intracellular staining of patients materials
Ficoll-separated PBMCs from patients or healthy donors were incubated with APC-anti-CD4, PerCP-anti-CD3, PE-anti-CD25 plus antibodies against human Jagged-1, Jagged-2 or DLL-1 to detect the expression of Notch-1 ligands. Meanwhile, certain PBMCs were fixed with formaldehyde, then permeabilized by methanol and an intracellular staining was performed with antibodies against cleaved Notch-1 (Val 1744), Jagged-1 (H-114), Jagged-2 (H-143) or DLL-1 (H-265). All of the antibodies to detect ligands of Notch-1 were purchased from Santa Cruz Biotechnology Inc. Samples were then incubated with Alexa-Fluor-488-conjugated secondary antibodies. The expression of target molecules was detected by a FACSCalibur.
Statistical analysis
The differences in the tumor size of mice in each group were determined by analysis of variance. Statistical significance of differences in survival of mice in different groups was determined by the log-rank test using JMP program (Abacus Concepts, Berkeley, CA, USA). Other data were analyzed using the Student's t-tests.
Triple combination treatment against ATL P Yu et al RESULTS Constitutive activation of Notch-1 in HTLV-1-associated ATL cell lines We previously reported that 40% of leukemia cells of ATL patients have activating Notch-1 mutations. 8 Initial studies were performed to examine the relative levels of Notch-1 in ATL cell lines. Among the five ATL cell lines assessed (MT-1, ED+, ED − , LM-Y1 and 43Tb − ), increased expression of ICN-1 was only detected in MT-1 cells by western blot analysis (Figure 1a) . Furthermore, direct sequencing of reverse transcription-PCR products of exon 34 demonstrated a missense mutation (C4T) at nucleotide position 7536 of the Notch-1 transcript. This results in a Pro 2513 Leu amino-acid substitution in the C-terminal PEST domain of Notch-1 (Figure 1b) . PEST domain mutations in T-ALL led to increased levels of ICN-1 because of impaired degradation of activated receptor by proteasomes. 7, 19 This is identical to the mutation found in several T-ALL lines and lies in a sequence that has been implicated in Fbw 7-mediated degradation of ICN-1. Compound E inhibited the proliferation and induced apoptosis in MT-1 cell lines We examined the effects of compound E and another γ-secretease inhibitor-RO4929097-on the proliferation of MT-1 cells. Various concentrations of inhibitors were used, and dose-dependent inhibition by compound E addition was observed in MT-1 cells (Figure 2a ). A similar pattern was shown in MT-1 by RO4929097 treatment (Figure 2b ). However, other ATL cell lines (ED+, LM-Y1 and 43Tb − ) that with no ICN-1 expression detected by western blot were not affected by either of these inhibitors. Only modest suppression at high concentrations of compound E was observed in ED − cells. This excludes off-target suppressive effects by compound E and RO4929097. HPB-ALL cells were used as a positive control carrying an activated mutation of Notch-1. 22 Jurkat cells were used as a negative control, noting that a PTEN mutation makes these cells resistant to GSIs. 23 Staining of MT-1 cells with Annexin-V demonstrated that a significant proportion of cells had undergone apoptosis 48 h after compound E treatment ( Figure 2c ). Both caspase-9 and -3 activities as measured by colorimetric assays were induced in the MT-1 cell line 24 h after compound E treatment ( Figure 2d Additive/synergistic inhibitory effect on MT-1 cells by the combination of compound E, bortezomib and romidepsin in vitro We quantitatively analyzed the changes in DNA-binding activity of the different NF-κB subunits after compound E treatment in MT-1 cells (Figure 5a ). Nuclear protein samples were prepared, and protein binding to NF-κB-responsive DNA oligonucleotides was analyzed with TransAM NF-κB Family Kit (Active Motif). To confirm the specificity of the assay, two oligonucleotides were provided as a competitor for NF-κB binding. Wild-type consensus oligonucleotides prevented NF-κB binding to the probe immobilized on the plate. In contrast, the mutated consensus oligonucleotide had no effect on DNA binding (data not shown). Strong reduction of DNAbinding activity was observed for the p52 and RelB subunits in MT-1 cells in a dose-dependent manner (Figure 5a ). Modest inhibition of the p65 subunit was detected with low-dose compound E treatment (Figure 5a ). No obvious suppression was detected on p50 or c-Rel. However, DNA-binding activity for p50 and c-Rel subunits was reduced upon bortezomib treatment in MT-1 cells (Figure 5b ). When we combined compound E with bortezomib, they effectively inhibited the NF-κB pathway in MT-1 cells (Figure 5b ). Our data support the view that Notch contributes to the regulation of alternative NF-κB signaling. 24 This suggests that in MT-1 cells, Notch inhibition exerts its biologic effects at least in part through downregulation of alternative NF-κB signaling. Moreover, the co-operation of bortezomib (1 nM) with romidepsin (2 nM) effectively triggered the caspase pathway with increased caspase-3 and -9 activity even at low doses, as shown in Figure 5c , compared with each agent alone (P o 0.05). Romidepsin (2 nM) along with the combination of compound E (1 μM) and bortezomib (1 nM), significantly inhibited the proliferation of MT-1 cells as assessed by an in vitro assay (Figure 5d ), when compared with that observed in single-agent or double combination-agent groups (P o0.05).
Effective treatment of ATL with compound E, bortezomib and romidepsin in MT-1 in vivo murine model of human ATL In the MT-1 model, a 4-week course of treatment with compound E, bortezomib, romidepsin and the combination of these agents demonstrated therapeutic efficacy as assessed by both tumor growth (Figure 6a ) and survival of tumor-bearing mice (Figure 6b ). Single-agent-and double combination-treated groups had significantly smaller tumors and longer survival times compared with control group (P o 0.05). Moreover, growth of tumors in the triple combination treatment group was reduced when compared with all other groups (P o0.05). Prolonged survival times of tumor bearing animals in the triple combination treatment group was observed when compared with control group (mean survival: 85 vs 36 days, P = 0.001); compound E-alone group (median survival: 85 vs 50 days; P = 0.025); bortezomib-alone group (median survival: 85 vs 44 days, P = 0.002); romidepsin-alone group (median survival: 85 vs 47 days, P = 0.009); compound E +bortezomib group (85 vs 53 days, P = 0.020); bortezomib +romidepsin group (85 vs 55 days, P = 0.028) and compound E +romidepsin (85 vs 51 days, P = 0.021). In the triple combination treatment group, 30-40% of the initially treated animals did not have detectable tumors at the study termination (100 days after tumor inoculation). Meanwhile, serum levels of human sIL-2Rα (CD25) and human β 2 M also reflected the therapeutic efficacy (Figures 6c and d) . Compared with serum concentrations of sIL-2Rα and β 2 M in the control group at 5 weeks after tumor inoculation, there were reductions of sIL-2Rα and β 2 M levels in triple combination-treated animals (sIL-2Rα, 1422 ± 130 vs 47608 ± 9000 pg/ml, P o0.01; β 2 M, 130 ± 46 vs 2000 ± 465 ng/ml, P o0.01). Furthermore, although single-agent and double combination treatment groups showed significant decreases in sIL-2Rα and β 2 M, the triple combination therapy group demonstrated a far greater decrease in these markers. After gating on CD3 low CD4 high cells, increased surface expressions of Notch ligands-Jagged-1, Jagged-2 and DLL-1-were detected in ATL-2 patient compared with normal PBMCs by flow cytometry (Figure 7b) . Among all ATL patients, increased surface expression of Jagged-1 (MFI = 26.9 ± 10.1) and Jagged-2 (MFI = 29.9 ± 14.2) was detected, compared with normal and ICN-1 low groups (P o 0.05). Meanwhile, intracellular expression levels of all three ligands were upregulated in the ICN-1 high group, with Jagged-1 (MFI = 123.5 ± 31.9), Jagged-2 (MFI = 190 ± 52.5) and DLL-1 (MFI = 185.9 ± 42.2), compared with ICN-1 low group and the normal donors group (P o 0.05; Figures 7c and d) .
Ex vivo ATL cells in PBMCs of

Ex vivo triple combination treatment induced early apoptosis of PBMCs of ATL cells from patients with increased ICN-1 expression
Ex vivo apoptosis assays of PBMCs in chronic/smoldering ATL patients with increased ICN-1 expression were performed by treating PBMCs with inhibitors. Apoptosis was determined by flow cytometric analysis using Annexin-V-FITC/PI staining. The percentage of early apoptotic cells was measured by defining the percentage of the Annexin-V + PI − cells after incubation with the indicated reagents (Figure 8a ). Statistical analysis suggested that the triple combination treatment significantly increased early apoptosis cells when compared with all single or double combination groups (P o 0.01; Figure 8b) . Moreover, the spontaneous proliferation observed with PBMCs from eight patients was inhibited by the addition of compound E, bortezomib and romidepsin (Figure 8c ). Statistical analysis suggested that the triple combination treatment significantly inhibited 6-day ex vivo spontaneous cell proliferation when compared with other single or double combination groups (Figure 8c ). Compared with normal donors and patients with low ICN-1 expression group ( Supplementary Figures 1 and 2 ), these data reflect the underlying correlation between increased ICN-1 expression and the response to compound E, bortezomib and romidepsin triple combination treatments.
DISCUSSION
Currently, there is no effective curative therapy for patients with HTLV-1-associated ATL. A number of strategies such as chemotherapy and anti-retroviral agents have been evaluated for the treatment of ATL patients without significant curative benefit. So far, there is no standard therapy for the majority of ATL patients. Given the limitations in treatment for these patients, newer therapeutic strategies are required.
Studies on T-ALL have suggested that Notch-1 is an important molecular target in this disease, 25 as half of the T-ALL patients have activating mutations in Notch-1.
7,26 Whereas significant numbers of HTLV-1-associated ATL patients have Notch-1 mutations, 8 the current therapeutic strategies have not included regimens targeting the Notch-1 signaling pathway.
Currently, in some of our chronic/smoldering ATL patients we have detected increased Notch-1 signal in the leukemic cells compared with unseparated normal CD4 + T cells in PBMCs by observing increased ICN-1 expression (Figure 7a) . In addition, we demonstrated that the spontaneous proliferation of PBMCs could be inhibited by the addition of compound E (Figure 8c ). These observations provide the scientific basis for the application of this inhibitor in the clinic for the treatment of patients with ATL. Meanwhile, Notch signaling is proving increasingly complex and it appears to be integrated with other pathways in normal and abnormal circumstances. There are reciprocal transcriptional regulations between Notch and NF-κB. 27 Specifically, Notch-1 has been reported to induce strongly NF-κB2 promoter activity in reporter assays. 28 In T-ALL, ICN-1 expression induced the nuclear localization of NF-κB, which resulted in the expression of multiple NF-κB targets (including Bcl-2A1, NF-κB2 and ICAM1). 22, 29, 30 These observations offer a complex picture of the interactions between Triple combination treatment against ATL P Yu et al these two pathways. Therefore, when we focus on the manipulation of the Notch signaling pathway for experimental or therapeutic purposes, it will be important to pay attention to the possible effects of Notch-1 manipulation on NF-κB and vice versa. This is especially true with certain ATL patients who have increased Notch-1 signaling along with upregulated NF-κB activity. Treatments inhibiting both pathways may be complementary. Currently in MT-1 cells, both canonical and noncanonical pathways exist and contribute to the constitutive NF-κB activity. 31 Vilimas et al. 32 reported that ICN-1 activated the NF-κB pathway by interacting with the IKK complex and by increasing transcription of NF-κB2 and Rel B. This was confirmed in our study: when low doses of compound E were provided to MT-1 cells, decreased DNA-binding activity of p52 and Rel B was observed (Figures 5a and b) . Meanwhile, with bortezomib, a proteasome inhibitor, potent inhibition of the growth of ATL cells both in vivo and in vitro was observed. The underlying mechanism was suggested to be caused by increased phosphorylation of IκBα protein in both cell lines and primary ATL cells. 33 This provided the scientific rational for our combination of low doses of bortezomib and compound E, which resulted in inhibition of DNA-binding activity of all five subunits of the NF-κB pathway (Figure 5b) . Furthermore, we obtained significantly increased cytotoxic activity with the combination when compared with either agent alone in vitro and in vivo (Figures 5d and 6 ). This observation is consistent with the reported additive/synergistic functions between GSIs and bortezomib. 34 With the presence of increased Notch-1 signaling in some ATL patients, a combination of low dose of GSI with bortezomib may lead to increased efficacy without serious toxicity.
Romidepsin belongs to the cyclic peptide class of HDAC inhibitors and is currently undergoing clinical trials as a treatment for cutaneous T-cell lymphoma, peripheral T-cell lymphoma and a variety of other cancers. Upon romidepsin treatment, significant apoptosis was induced in HTLV-1-infected T-cell lines. 16 More importantly, it was reported in various disease models, including multiple myeloma and Mantle cell lymphoma, that there is synergy between bortezomib and HDAC inhibitors. [35] [36] [37] In chronic lymphocytic leukemia, bortezomib blocked romidepsin-mediated RelA acetylation, prevented romidepsin from induction of NF-κB activation and the de novo expression of its target gene IκBα. Moreover, this combination triggered a cell apoptosis pathway, reflected by caspase activation, and finally led to cell death of both primary chronic lymphocytic leukemia and cell lines. 38 Currently, whereas exposure to low doses of each agent alone resulted in slight increases of caspase-3 and -9 in MT-1 cells, the combined treatment resulted in a clear increase in activation of caspase-3 and -9, as well as cell death (Figures 5c and d) . In addition, the combination of bortezomib with romidepsin provided more pronounced cytotoxic activity than either agent alone in both an animal model and with patients ex vivo PBMCs (Figures 6 and 8) .
The Notch-1 signaling pathway is initiated upon ligand binding and the Notch-1 receptor is cleaved by the γ-secretase complex and the released ICN-1. DLL-1 and Jagged-1 are processed in a manner similar to Notch-1, ultimately resulting in the release of a nuclear-targeted intracellular domain. 39, 40 More importantly, Delta ligand was shown to be colocalized with the extracellular domain of Notch (NECD), which means NECD forms a complex with Delta. This is critical for Notch activation and is required to achieve processing and dissociation of the Notch protein. Thus, subsequent Notch signaling is dependent on Delta endocytosis and NECD trans-endocytosis. 41 Intriguingly, it has been reported that Jurkat cells, primary Hodgkin Reed-Sternberg cells and anaplastic large cell lymphoma cells express both Notch-1 and Jagged-1. 42, 43 Both DLL-1 and Jagged-1 have been detected in glioma cell lines and primary human gliomas. 44 Furthermore, studies have shown that in B-ALL cells that expressed all Notch receptors and ligands, the reciprocal cell interactions via Notch signaling played an important role in the leukemia cell survival. 45 Currently, we observed increases in both surface and intracellular expressions of Notch-1 ligands in some ATL leukemia cells along with upregulated ICN-1 expression.
Previous studies on T-ALL focused on the activating mutations of Notch-1. Recently, researchers have suggested that the induction of T-cell leukemia is dependent on the signaling strength of Notch-1 and that the signal strengths of the more common Notch-1 mutation alleles are insufficient to induce T-ALL on their own. Thus, Notch-1 mutations appear to be additional events that can cooperate with oncogenic hits and thereby influence tumor development and onset. 24 Importantly, these tumors seem to remain 'addicted' to Notch-1 signaling, 46 which justified further exploration of notch inhibitors in the treatment of T-cell leukemia. In our current study, among 14 ATL patients, only ATL-4 was shown to carry a Notch-1 mutation (Table 1 , ATL-21). 8 This different incidence from our previous report might be because of the different set of patients studied, which in the present case was predominantly at the early stage of smoldering/ chronic ATL. Nevertheless, 8 of 14 were shown to highly express ICN-1. Furthermore, after gating on CD3 low CD4 high T cells, there was significantly increased expression of Notch-1 ligands in the ICN-1 high ATL patient group detected by both surface and intracellular staining (Figures 7b-d) . Thus, it appears that Notch-1 signaling can be activated by its ligands expressed in ATL leukemia cells through homotypic or heterotypic cell-cell interactions, thereby providing an autocrine or reciprocal activation of Notch-1 signaling among the ATL leukemia cells that favor their own survival. In summary, the functional interactions between Notch and NF-κB provide the scientific basis for a rational drug combination therapy. The coactivation of Notch-1 and NF-κB exists in select ATL patients, thereby providing a valuable rational for the application of a combination therapeutic strategy. Our results support the clinical development of a combination therapy that includes a GSI that might serve as an effective therapeutic agent in patients with chronic/smoldering ATL whose cells express increased Notch-1 signaling. In conclusion, our data demonstrated that one of the GSIs-compound E-had antitumor activity both in vitro and in vivo. Furthermore, combination therapy of compound E, bortezomib with romidepsin had significantly greater therapeutic effects in the MT-1 murine model of ATL than any single agent alone or any of the pairs of agents. The results of our study support a trial of GSI in ATL patients, preferably as an agent in combination with bortezomib and romidepsin. The triple combination effectively suppressed spontaneous proliferation in certain chronic/smoldering ATL patients. The 6-day spontaneous proliferation of ex vivo PBMCs was assayed on cells from chronic/smoldering ATL patients by 3 H-TdR incorporation. Inhibitors were provided alone or in combination (2 μM compound E, 2 nM bortezomib and 1 nM romidepsin). In the presence of the triple combination, the spontaneous proliferation was inhibited significantly (*P o0.01 compared with DMSO group; $ P o0.05 compared with single-agent treatment groups; # P o0.05 compared with two combination treatment groups) (N = 8).
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